Citigroup maintains a 'Buy' rating for Zymeworks Inc. following its strategic acquisition of Theravance Biopharma, which aims to diversify cash flows and combine R&D with revenue-generating assets. The acquisition includes the product YUPELRI, expected to provide immediate revenue and enhance earnings per share. Zymeworks updated its 2026 guidance, projecting total revenue between $278 million and $292 million, and Adjusted EBITDA between $114 million and $128 million, signaling strong financial prospects ahead.
Citigroup shares trade at USD 130.76 on Pluang as of Sep 29, 2026 21:39 WIB, down 0.44% for the day. The platform shows a market cap of $220.26 billion and a dividend yield of 2.04%. This trading context coincides with Citigroup's affirmation of a Buy rating for Zymeworks following its strategic acquisition, highlighting investor interest in financial sector moves linked to biotech developments.
SoFi Technologies' stock has fallen over 43% in the past year, trading near its 52-week low at $15.93. Despite this, a Citigroup analyst maintains a strong Buy rating with a $30 target, suggesting an 88% upside based on SoFi's growing deposits, cross...
Citigroup lowered ACADIA Pharmaceuticals' price target from $40 to $33 after its Alzheimer's drug remlifanserin missed the primary goal in a mid-stage trial, causing a 10.5% stock drop. Despite this, Citigroup kept a "Buy" rating, citing promising se...
